Ciprofibrate
Ciprofibrate.JPG

Ciprofibrate

CLINICAL USE

Hyperlipidaemia

DOSE IN NORMAL RENAL FUNCTION

100 mg daily

PHARMACOKINETICS

  • Molecular weight                           :289.2
  • %Protein binding                           :95–99
  • %Excreted unchanged in urine     : 20–25
  • Volume of distribution (L/kg)       :12 litres
  • half-life – normal/ESRD (hrs)      :38–86/171.9

    DOSE IN RENAL IMPAIRMENT

    GFR (mL/MIN)

  • 20 to 50     : Dose as in normal renal function
  • 10 to 20     : 100 mg every 48 hours
  • <10           : Avoid. See ‘Other Information’

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

  • CAPD                :Not dialysed. Avoid
  • HD                     :Not dialysed. Avoid
  • HDF/high flux   :Unknown dialysability. Avoid
  • CAV/VVHD      :Unknown dialysability. Dose as in GFR 10 to 20 mL/min

    IMPORTANT DRUG INTERACTIONS

    Potentially hazardous interactions with other drugsAntibacterials: increased risk of myopathy with daptomycin – try to avoid concomitant useAnticoagulants: enhances effect of coumarins and phenindione. Dose of anticoagulant should be reduced by up to 50% and readjusted by monitoring INRAntidiabetics: may improve glucose tolerance and have an additive effect with insulin or sulphonylureasLipid-regulating drugs: increased risk of myopathy in combination with statins (do not exceed 10 mg of simvastatin1) and ezetimibe – avoid concomitant use with ezetimibe

    ADMINISTRATION

    Reconstition

    Route

    Oral

    Rate of Administration

    Comments

    OTHER INFORMATION

    Increased risk of rhabdomyolysis in doses of 200 mg or greaterApproximately 30–75% of a single dose administered to volunteers was excreted in the urine in 72 hours, either as unchanged ciprofibrate (20–25% of the total excreted) or as a conjugate. Subjects with moderate renal impairment excreted on average 7% of a single dose as unchanged ciprofibrate over 96 hours, compared with 6.9% in normal subjects. In subjects with severe insufficiency this was reduced to 4.7%



    See how to identify renal failure stages according to GFR calculation

    See how to diagnose irreversible renal disease

    Home

  • other drugs